Bicycle Therapeutics (BCYC) Non-Current Assets (2018 - 2026)
Bicycle Therapeutics posted quarterly Non-Current Assets of $20.3 million for Q1 2026, up 31.21% year-on-year from $15.4 million in Q1 2025, and down 7.48% on a QoQ basis from $21.9 million in Q4 2025.
Bicycle Therapeutics (BCYC) has 9 years of Non-Current Assets data on file, last reported at $20.3 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets rose 31.21% year-over-year to $20.3 million; the trailing twelve-month figure through Mar 2026 stood at $20.3 million (up 31.21% YoY), and the FY2025 full-year result was $21.9 million, up 27.45% from the prior year.
- Non-Current Assets for Q1 2026 stood at $20.3 million, down from $21.9 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $37.0 million in Q1 2023 and bottomed at $11.4 million in Q3 2025.
- The 5-year median for Non-Current Assets is $24.8 million (2024), against an average of $24.5 million.
- The widest annual swing landed in 2022, when Non-Current Assets soared 442.27%; it then slumped 44.58% in 2025.
- A 5-year view of Non-Current Assets shows it stood at $32.8 million in 2022, then decreased by 15.52% to $27.7 million in 2023, then sank by 37.91% to $17.2 million in 2024, then rose by 27.45% to $21.9 million in 2025, then fell by 7.48% to $20.3 million in 2026.
- The last three Non-Current Assets figures came in at $20.3 million (Q1 2026), $21.9 million (Q4 2025), and $11.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Bicycle Therapeutics | 326.82 Mn | 326.82 Mn | - | 20.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.27 Mn |
| Dec 31, 2025 | 21.91 Mn |
| Sep 30, 2025 | 11.42 Mn |
| Jun 30, 2025 | 14.11 Mn |
| Mar 31, 2025 | 15.45 Mn |
| Dec 31, 2024 | 17.19 Mn |
| Sep 30, 2024 | 20.61 Mn |
| Jun 30, 2024 | 22.52 Mn |
| Mar 31, 2024 | 24.81 Mn |
| Dec 31, 2023 | 27.68 Mn |
| Sep 30, 2023 | 30.20 Mn |
| Jun 30, 2023 | 33.59 Mn |
| Mar 31, 2023 | 36.98 Mn |
| Dec 31, 2022 | 32.77 Mn |
| Sep 30, 2022 | 29.70 Mn |
| Jun 30, 2022 | 31.89 Mn |
| Mar 31, 2022 | 25.60 Mn |
| Dec 31, 2021 | 17.79 Mn |
| Sep 30, 2021 | 5.68 Mn |
| Jun 30, 2021 | 5.88 Mn |
| Mar 31, 2021 | 6.27 Mn |
| Dec 31, 2020 | 3.61 Mn |
| Sep 30, 2020 | 3.50 Mn |
| Jun 30, 2020 | 3.80 Mn |
| Mar 31, 2020 | 4.02 Mn |
| Dec 31, 2019 | 4.35 Mn |
| Sep 30, 2019 | 4.33 Mn |
| Jun 30, 2019 | 4.39 Mn |
| Dec 31, 2018 | 1.82 Mn |